These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34413026)

  • 1. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 3. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 5. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 6. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 7. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 11. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 13. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 14. Aducanumab and the FDA - where are we now?
    Fillit H; Green A
    Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
    [No Abstract]   [Full Text] [Related]  

  • 15. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

  • 16. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 17. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    Emanuel EJ
    JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: How Will Aducanumab Approval Impact AD Research?
    Weiner MW; Aisen PS; Beckett LA; Green RC; Jagust W; Morris JC; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ
    J Prev Alzheimers Dis; 2021; 8(4):391-392. PubMed ID: 34585209
    [No Abstract]   [Full Text] [Related]  

  • 19. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
    Lythgoe MP; Prasad V
    Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.